Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03459352 · ClinicalTrials.gov registry record · NA

Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients

A NA study of Cancer, sponsored by Duke University.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT03459352: Completed NA study of Cancer, sponsored by Duke University.

NCT03459352 is a NA study of Cancer that has completed, run by Duke University. The registered enrollment target is 38 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03459352, a NA study of Cancer, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

A pilot study of an ePRO system in cancer patients receiving systemic therapies.

Primary Outcome

total number of subjects that participate in the use of a web-based system

Conditions Studied

Interventions

  • OTHER ePRO

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2018-06-18
Est. Completion 2020-04-04
Phase NA
Duke University

1,725 total trials

What the finished NCT03459352 record still lists

NCT03459352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which ePRO is the first listed.

NCT03459352 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT03459352 about?

NCT03459352 is a clinical study titled "Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients". A pilot study of an ePRO system in cancer patients receiving systemic therapies.

What is the current status of trial NCT03459352?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2018-06-18. Estimated completion is 2020-04-04.

What conditions does trial NCT03459352 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT03459352?

The interventions under investigation include: ePRO (OTHER).

Who is sponsoring clinical trial NCT03459352?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03459352 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03459352's enrollment target sits among peer trials

38 476th of 615 higher than 135 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

  • NCT04237623 · 38 participants · Phase 2

    GM-CSF With Post-Transplant Cyclophosphamide

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03459352, the US trial registry maintained by the National Library of Medicine. NCT03459352 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.